New Alzheimer’s Drugs Raise Questions for Regulators
Key Points Summary New Alzheimer’s drugs such as donanemab and lecanemab are generating optimism but remain controversial due to modest
Read MoreKey Points Summary New Alzheimer’s drugs such as donanemab and lecanemab are generating optimism but remain controversial due to modest
Read MoreKey Takeaways Microplastics and nanoplastics (MPs/NPs) can cross the blood–brain barrier and accumulate in neural tissue Experimental models link plastic
Read MorePoor kidney function may influence levels of Alzheimer’s biomarkers, but not necessarily dementia risk, according to new findings published in
Read More